Coherus Q3 revenue $70.8M, UDENYCA up 30% QoQ; net loss narrows to $10.8M from $39.6M YoY

Coherus Oncology, Inc.

2024-Q3 EPS reported $0.65 revenue$212,816,000

Net revenue $70.8M; UDENYCA $66.1M (+30% QoQ, +100% YoY); LOQTORZI $5.8M (+54% QoQ).
Net loss $10.8M ($0.09 loss per share) vs $39.6M loss in Q3 2023; non-GAAP net loss $1.7M.
UDENYCA supply: CMO resumes production; backlog ~120k units expected by year-end; new CMO testing, commercial supply Q1 2025.
Pipeline: Phase 2 HCC study of casdozokitug+toripalimab+bevacizumab opening; CHS-114 Phase 1 data expected H1 2025.
Gross profit improved on divested products (CIMERLI, YUSIMRY); SG&A down $13.5M YoY on lower headcount.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.